Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) declines year over year
Q1 FY2026 EPS (Basic) of $0.06 fell 100.0% year over year, in line with the -99.8% change in trailing-twelve-month EPS (Basic). Sequentially, it rose 852.4% from the prior quarter.
What to watch
Whether quarterly growth recovers from -100.0% toward the trailing-twelve-month pace of -99.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- 0.19 USD
- Year-over-year change
- +439.3%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0.19 | +439.3% |
| FY2024 | 2024-12-31 | (0.06) | — |
EPS (Basic) vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 EPS (Basic) of $0.2 is the 8th highest of the 10 companies compared; the peer median is $0.29.
- Its year-over-year change of -99.8% is the lowest of 5, against a peer median of +130.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.35 | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | $0.34 | +928.3% | — |
| LTM Mar 2026 | $0.32 | -31.4% | — | |
OYSEOyster Enterprises II Acquisition Corp | LTM Mar 2026 | $0.3 | — | — |
| LTM Mar 2026 | $0.29 | +24.2% | — | |
| LTM Mar 2026 | $0.26 | +236.7% | -13.7% | |
| LTM Mar 2026 | $0.25 | — | — | |
| LTM Mar 2026 | $0.2 | -99.8% | — | |
TACOUBerto Acquisition Corp. Unit | LTM Mar 2026 | $0.19 | — | — |
| LTM Mar 2026 | -$0.34 | — | — | |
| Peer median (excluding DMAA) | $0.29 | +130.5% | -13.7% | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 480 | 2.82M |
| Operating Expenses | 480 | 2.82M |
| Depreciation & Amortization | 480 | 0 |
| EBITDA | (279.85K) | (2.82M) |
| EBITDA Margin | — | — |
| Operating Income | (479) | (2.82M) |
| Operating Margin | — | — |
| Interest Income | 0 | 8.76M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 0 | 8.76M |
| Income Before Tax | (479) | 5.94M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | (479) | 5.94M |
| Net Margin | — | — |
| EPS (Basic) | (0.06) | 0.19 |
| EPS (Diluted) | (0.06) | 0.19 |
| Weighted Avg Shares | 8.57M | 21.01M |
| Weighted Avg Shares (Diluted) | 8.57M | 21.01M |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.